MOTS-c vs Humanin

Overview

MOTS-c and Humanin are both mitochondria-derived peptides (MDPs) - a novel class of signaling molecules encoded within mitochondrial DNA. Discovered in the 21st century, they represent endogenous factors that decline with age and are being studied for their potential roles in metabolic health, neuroprotection, and longevity. While both originate from mitochondria, they work through distinct mechanisms.

This comparison is highly relevant for longevity researchers as both peptides are key targets in the emerging field of mitochondrial-derived peptide biology.

Key Facts

Aspect	MOTS-c	Humanin
Full Name	Mitochondrial ORF of 12S rRNA type-c	Humanin
Discovery	2015 (Lee/Cohen)	2001 (Hashimoto)
Structure	16 amino acids	24 amino acids
Encoding	12S rRNA gene (mtDNA)	16S rRNA gene (mtDNA)
Primary Action	Metabolic regulation	Cytoprotection
FDA Status	Not approved	Not approved

Mitochondrial Origins

Aspect	MOTS-c	Humanin
mtDNA Location	12S rRNA	16S rRNA
Discovery Context	Metabolic research	Alzheimer’s research
Secreted	Yes (systemic)	Yes (systemic)
Age-Related Decline	Yes	Yes

Significance of MDP Discovery

Both peptides represent a paradigm shift: mitochondrial DNA, once thought to encode only for oxidative phosphorylation components, actually produces bioactive signaling peptides that regulate whole-body physiology.

Mechanism Comparison

Aspect	MOTS-c	Humanin
Primary Target	AMPK pathway	FPRL1/2 receptors, BAX
Action	Metabolic regulation	Anti-apoptotic
Key Effect	Exercise mimetic	Cytoprotective
Nuclear Translocation	Yes (under stress)	No (receptor-mediated)

MOTS-c Mechanisms

1. AMPK Activation

   • Master metabolic regulator
   • Shifts cells to maintenance mode
   • Mimics exercise effects

2. mTOR Suppression

   • Promotes autophagy
   • Reduces growth signaling
   • Longevity pathway

3. Nuclear Gene Regulation

   • Translocates to nucleus under stress
   • Nrf2-ARE pathway activation
   • Antioxidant response genes

4. Metabolic Effects

   • Improved glucose uptake
   • Enhanced insulin sensitivity
   • Fatty acid oxidation

Humanin Mechanisms

1. Receptor Signaling

   • FPRL1/2 receptor binding
   • ERK1/2 and STAT3 activation
   • Anti-apoptotic gene expression

2. BAX Inhibition

   • Direct binding to pro-apoptotic BAX
   • Prevents mitochondrial permeabilization
   • Blocks death cascade

3. Cytoprotection

   • Protects neurons from toxicity
   • Guards against amyloid-beta
   • Broad anti-stress effects

4. IGF Modulation

   • IGFBP-3 binding
   • Modulates insulin/IGF signaling

Evidence Quality

Factor	MOTS-c	Humanin
Human Studies	6 (biomarker/correlational)	10 (biomarker/correlational)
Animal Studies	22	40+
Cell Studies	Extensive	Extensive
Clinical Trials	None	None
Overall Evidence	Low	Moderate

Research Status Comparison

Aspect	MOTS-c	Humanin
Discovery Date	2015	2001
Research Years	~10 years	~25 years
Total Publications	~100	~500+
Independent Labs	Growing (Cohen lab primary)	Many worldwide
Mechanism Understanding	Developing	Well-characterized

Human Biomarker Data

MOTS-c in Humans

Finding	Source	Implication
Lower in Type 2 diabetes	Multiple studies	Metabolic link
Declines with age	Lee et al.	Age association
Increases with exercise	Reynolds 2019	Exercise connection
K14Q variant = longevity	Japanese studies	Genetic link

Humanin in Humans

Finding	Source	Implication
Declines with age	Multiple studies	Age association
Lower in Alzheimer’s	Biomarker studies	Disease correlation
Inverse to insulin resistance	Lee 2015	Metabolic link
Higher = preserved cognition	Cobb 2016	Cognitive protection

Longevity Research

MOTS-c Aging Studies

Model	Finding	Source
Aged mice (22 mo)	Improved physical capacity	Reynolds 2021
Pancreatic islets	Reduced senescence markers	D’Souza 2020
OVX mice	Prevented metabolic decline	Kim 2019
Japanese centenarians	K14Q variant associated	Genetic studies

Humanin Aging Studies

Model	Finding	Source
Multiple disease models	Cytoprotective effects	Multiple
APP transgenic mice	Reduced pathology	Tajima 2005
Biomarker studies	Higher levels = longevity phenotype	Cobb 2016
Heart/kidney models	Protective effects	Multiple

Disease Application Research

MOTS-c Applications

Area	Evidence	Rationale
Metabolic syndrome	Preclinical	AMPK activation
Type 2 diabetes	Biomarker + preclinical	Glucose regulation
Aging/healthspan	Preclinical	Exercise mimetic
Osteoporosis	Early preclinical	Bone metabolism

Humanin Applications

Area	Evidence	Rationale
Neurodegeneration	Preclinical	Anti-apoptotic, anti-amyloid
Cardiovascular	Preclinical	Cytoprotection
Metabolic disease	Preclinical	Insulin sensitivity
Aging	Biomarker	Decline with age

Administration Research

Aspect	MOTS-c	Humanin
Research Route	Subcutaneous	Subcutaneous
Bioavailability	Under study	Under study
Analogs	Being developed	HNG (potent analog)
Half-life	Being studied	Being studied

Analog Development

Peptide	Analog	Purpose
MOTS-c	MOTS-c analogs	Improved stability
Humanin	HNG (S14G-Humanin)	1000x more potent
Humanin	Colivelin	Combination peptide

Safety Considerations

MOTS-c

Concern	Note
Human safety data	None (no trials)
Endogenous nature	May suggest tolerability
mTOR suppression	Long-term effects unknown
Metabolic effects	Blood sugar monitoring

Humanin

Concern	Note
Human safety data	None (no trials)
Anti-apoptotic effects	Theoretical cancer concern
Endogenous nature	May suggest tolerability
Complex biology	Multiple mechanisms

Synergy Potential

Factor	Evidence
Complementary mechanisms	AMPK vs anti-apoptotic
Both decline with age	Replacement rationale
Different disease targets	Metabolic vs neuroprotective
Combination studies	None conducted

Theoretical Combined Approach

• MOTS-c: Metabolic optimization, exercise mimetic
• Humanin: Cellular protection, anti-apoptotic
• Together: Multi-target aging intervention

Regulatory and Availability

Aspect	MOTS-c	Humanin
FDA Status	Not approved	Not approved
Clinical Development	Not active	Not active
Research Chemical	Available	Available
Pharmaceutical	None	None
Quality Assurance	Variable	Variable

Summary

Factor	MOTS-c	Humanin
Structure	16 amino acids	24 amino acids
mtDNA Location	12S rRNA	16S rRNA
Primary Action	Metabolic regulation	Cytoprotection
Mechanism	AMPK activation	FPRL/BAX inhibition
Evidence Level	Low	Moderate
Research Years	~10	~25
Human Trials	None	None
Age Association	Declines	Declines

Key Takeaways

1. Both are MDPs: Encoded in mitochondrial DNA - novel signaling class
2. Different mechanisms: MOTS-c is metabolic; humanin is cytoprotective
3. Both decline with age: Suggests role in aging process
4. Humanin has more research: 25 years vs 10 years of study
5. Neither has human trials: Despite extensive preclinical data
6. Complementary potential: Different pathways may combine well
7. Exercise connection: MOTS-c increases with exercise; mimics benefits
8. Neuroprotection focus: Humanin discovered for Alzheimer’s protection

---

This comparison is for educational purposes only. Neither peptide is approved for any clinical use. Both are research compounds with no completed human therapeutic trials.